IBB – In The Decision Zone

iShares Nasdaq Biotechnology (IBB) -Nasdaq The best indicator for our biotech portfolios are biotechnology indices such as IBB, NBI, XBI or XLV. By looking at the IBB daily chart, we get the whole picture of the latest epic run in the biotech sector during 2013, with a whopping run from 134.21 to 227.06 points, gaining 69.2%, while […]

BMY – Quick Chart Update

Bristol-Myers Squibb Company (BMY)  -NYSE   Interesting price action since September 9th after breaking out the downtrend line around $41.90, we kept watching the chart day after day during the preparation to AASLD reaching the high of $47.90, followed by a price consolidation and forming a flag pattern that we discussed several times through the private […]

ONTX – Looking For The Reversal Pattern

Onconova Therapeutics, Inc. (ONTX) -Nasdaq   Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the low of $12.03 today. Surprising given the Phase 3 readout coming up and final results from the Phase-II trial of oral rigosertib in 1st-line Low-Risk […]

Merck – Quick Chart Review

Merck & Co. Inc. (MRK) -NYSE For the first time since March 1st, MRK’s price dropped below its 200-Day Moving Average. This is worth a deeper look at the price action and the indicators are showing a “Bullish Divergence” and within the oversold zone. Merck will take part at the (IASLC) the 15th World Conference on […]

ACHN – In Consolidation Mode

Achillion Pharmaceuticals, Inc. (ACHN – Nasdaq) On  July 1, 2013 the FDA placed a clinical hold on Achillion’s hep C drug and the shares plunged 22% from $8.36 to $6.17 the next morning. Since then the shares have traded sideways in a horizontal channel between $6.12 to $7.32.  In the second quarter earnings press release Achillion […]

PGNX – Preparing For The Next Run

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq Since my latest “Chart & TA” report “PGNX – A Hidden Bullish Divergence” on Aug 22nd, 2013. PGNX  has been trading up and gained 33% in just 9 trading days, breaking out several resistance lines as I predicted in the last TA report What’s Next The price at this level around the […]

AMRN – Another Breakout – Chart Update

Amarin Corporation plc (AMRN) -Nasdaq Since my latest “Chart & TA” report AMRN – Running Up To The AdCom on Aug 30th, 2013. AMRN kept trading up and gained 4.7% , reaching the downtrend line (brown color on the chart) around $6.65. There we witnessed a real control’s war between the bulls and the bears around 12:15 […]

RPTP – New All Time High

Raptor Pharmaceuticals Corp. (RPTP) -Nasdaq Opportunity knocks all the time, but you have to be ready for it. If the chance comes, you must be ready and quickly respond to take advantage of it. On Aug 29. 2013 Gravity Research initiate a bearish report “Initiating Coverage on Raptor Pharmaceutical Corporation (NASDAQ:RPTP) – Strong Sell” causing a […]

AMRN – Running Up To The AdCom

Amarin Corporation plc (AMRN) -Nasdaq The price closed above the 100-Day moving avarage and the $6.34 resistance line, while the indicators still positive and wants more upside. The next important line to breakout is the Brown downtrend line around $6.70 that will make the weekly resistance line at $7.56 as the next target. Expect some technical correction […]

PGNX – A Hidden Bullish Divergence

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq On June 11, 2013 Progenics and Salix (partner) announced an FDA Advisory Committee (AdCom) is scheduled to review Relistor sNDA for opioid-induced constipation(OIC) in patients with chronic pain. On July 27, 2012 Salix (SLXP) and Progenics received CRL from the FDA regarding the RELISTOR sNDA. But Slaix filed a formal appeal […]

IBB – Technical Commentary

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolio are the biotechnology indices IBB, NBI, XBI or XLV. After publishing “IBB – Biotechnology Index at All Times High“, we wanted to maintain our focus on the IBB. In today’s video “IBB – Market Activity” Tony noted a large bearish bet or hedge […]

DEPO – Action Ahead Of The AdCom

DepoMed Inc. (DEPO) -Nasdaq Serada is an investigational formulation of gabapentin, an FDA-approved immediate release pharmaceutical for the treatment of partial epilepsy and management of postherpetic neuralgia (PHN). Recently published studies suggest the potential application of gabapentin for the treatment of menopausal hot flashes. Based on these findings, Depomed has secured exclusive rights to develop […]